MicroGenDX

Biotechnology ResearchFlorida, United States51-200 Employees

MicroGenDX is a mid-sized biotechnology research and clinical laboratory headquartered in Orlando, Florida, delivering infectious-disease testing that combines qPCR with next-generation sequencing. The organization is CAP-accredited and CLIA-licensed, and its testing framework has been recognized by the AMA and Medicare with a billing code as medically necessary.

Its services are used by physicians worldwide across hospitals, long-term care facilities, dental offices, and veterinary clinics, addressing infections ranging from chronic wounds to respiratory and urinary tract infections. The NGS-based testing can detect a broad range of organisms, including those that are difficult to culture, and provides faster, more comprehensive results with species- or strain-level identification. In February 2025, MicroGenDX announced the launch of Rapid H5, a qPCR test targeting avian influenza A H5 variants, illustrating ongoing expansion of its diagnostic offerings.

Sign up for free to view info

Email Format Employee directory